Phase 2 COVID-19 Vaccine Variant Clinical Trial

$368.55M USD

Funder	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Recipient Organization	Leidos Biomedical Research, Inc.
Country	United States
Start Date	Mar 07, 2022
End Date	Mar 06, 2024
Duration	730 days
Number of Grantees	1
Roles	Principal Investigator
Data Source	NIH (US)
Grant ID	`10683817`

Grant Description

To support a Phase 2 clinical trial evaluating various additional COVID-19 booster shots, the COVID-19 Variant Immunologic Landscape (COVAIL) clinical trial.